Stocks Comparison
Idexx Laboratories vs Trinity Biotech: revenue, profit, margins and growth compared
Idexx Laboratories brought in $4.3B of revenue in fiscal 2025, Trinity Biotech $61.6M in fiscal 2024. Revenue changed by +10.4% at Idexx Laboratories and +8.3% at Trinity Biotech on the year before, so Idexx Laboratories grew faster. Idexx Laboratories kept 24.6% of its revenue as net profit, Trinity Biotech -51.6%. Free cash flow was $1.1B at Idexx Laboratories and -$4.6M at Trinity Biotech.
Side by side, latest fiscal year
| IDXX | TRIB | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2024 (December 31, 2024) |
| Revenue | $4.3B | $61.6M |
| Revenue growth | +10.4% | +8.3% |
| Net income | $1.1B | -$31.8M |
| Net margin | 24.6% | -51.6% |
| Free cash flow | $1.1B | -$4.6M |
| Free cash flow margin | 24.6% | -7.5% |
| Earnings per share (diluted) | $13.08 | n/a |
| Cash | $180.1M | $5.2M |
| Debt | $450M | n/a |
| Price to earnings | 39.7 | n/a |
| Market value | $40.9B | $5.5M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #68 of 646 · Health care | #358 of 646 · Health care |
Over the years
Questions about Idexx Laboratories and Trinity Biotech
Which is bigger by revenue, Idexx Laboratories or Trinity Biotech?
Idexx Laboratories is bigger by revenue: $4.3B in fiscal 2025, against $61.6M for Trinity Biotech in fiscal 2024.
Which keeps more of its revenue as profit, Idexx Laboratories or Trinity Biotech?
Idexx Laboratories had a net margin of 24.6% in fiscal 2025; Trinity Biotech had -51.6% in fiscal 2024.
Which grew revenue faster, Idexx Laboratories or Trinity Biotech?
In their latest fiscal years revenue changed by +10.4% at Idexx Laboratories and +8.3% at Trinity Biotech.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.